Saturday, September 6, 2025
  • Login
Forbes 40under40
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle
No Result
View All Result
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle
No Result
View All Result
Forbes 40under40
No Result
View All Result
Home Lifestyle

Pfizer’s Covid-19 drug powers strong quarterly profit as activist hovers

by Mark Darwin
in Lifestyle
Pfizer’s Covid-19 drug powers strong quarterly profit as activist hovers
Share on FacebookShare on Twitter


Pfizer, which is under pressure from activist investor Starboard, on Tuesday (Oct 29) topped third-quarter estimates as sales of its Covid-19 treatment Paxlovid blew past Wall Street expectations.

The US drugmaker has struggled with a sharp fall in sales of its Covid vaccine and antiviral pill Paxlovid from pandemic levels, prompting it to launch a cost-cutting programme last year and focus on deals to bolster its business.

On Tuesday, the company said the better-than-expected growth for Paxlovid reflected higher infection rates and “strong commercial execution.”

“The demand for Paxlovid seems to have stabilised at the current levels and appears to be closely correlated with each wave of Covid-19,” CEO Albert Bourla said in prepared remarks.

Shares rose 1.5% to US$29.30 in premarket trading after the company also raised its annual profit and sales forecast.

Its shares trade at roughly half of their pandemic peaks. Activist hedge fund Starboard Value, investors and analysts have said they want to see improved profitability from the cost cuts and revenue growth powered by its recent deals.

BT in your inbox

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Revenue from Paxlovid was US$2.7 billion in the quarter, compared with analysts’ expectations of US$456.40 million.

JP Morgan analyst Chris Schott said that the antiviral benefited from an earlier Covid season and what appears to be higher-than-expected commercial pricing. The US experienced a late summer spike in Covid-19 cases this year.

Covid vaccine Comirnaty, which Pfizer makes with German partner BioNTech, brought in quarterly sales of US$1.42 billion, compared with expectations of US$870 million, according to estimates compiled by LSEG.

The blockbuster quarter also encouraged Pfizer to bump up its annual revenue expectations from Comirnaty and Paxlovid to US$10.5 billion, from its previous forecast of US$8.5 billion.

Analysts expect sales of about US$9 billion from both the products this year.

Pfizer now expects annual profit to be in the range of US$2.75 to US$2.95 per share, compared with its prior forecast of US$2.45 to US$2.65.

On an adjusted basis, Pfizer earned US$1.06 per share in the third quarter, compared with the average analyst estimate of 62 US cents.

Total revenue of US$17.70 billion beat estimates of US$14.96 billion. REUTERS

Tags: ActivistCovid19DrughoversPfizersPowersProfitQuarterlyStrong
Mark Darwin

Mark Darwin

Next Post
Israel’s Top General Exposes Hezbollah’s Hidden War Tunnels Designed for Military Operations in Lebanon

Israel's Top General Exposes Hezbollah's Hidden War Tunnels Designed for Military Operations in Lebanon

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.

 
 
 
 

NEWS

  • Forbes Magazine
  • Technology
  • Innovation
  • Money
  • Leadership
  • Real Estate
  • Lifestyle
Instagram Facebook Youtube

© 2025 Forbes 40under40. All Rights Reserved.

  • About Us
  • Advertise
  • Contact Us
No Result
View All Result
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle

© 2024 Forbes 40under40. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In